熱門資訊> 正文
MAIA Biotechnology宣布151万美元私募
2025-12-17 05:33
- MAIA Biotechnology (NYSE:MAIA) announced on Tuesday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.23M shares of common stock at a price of $1.224 per share in a private placement.
- Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.36 per share.
- The warrants are exercisable six months following issuance and have a term of three years from the issuance date.
- The private placement is expected to close on or about December 18, 2025.
- The gross proceeds are expected to be approximately $1.51M, and the company plans to use the net proceeds to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- Shares -8.89%.
More on MAIA Biotechnology
- MAIA Biotechnology announces $0.74M private placement
- MAIA Biotechnology adopts crypto treasury strategy; shares up
- Seeking Alpha’s Quant Rating on MAIA Biotechnology
- Historical earnings data for MAIA Biotechnology
- Financial information for MAIA Biotechnology
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
